Scientists Call for Multi‑Target Alzheimer’s Strategy
Why it matters: Monoclonal antibodies only slow decline by ~20% in early‑stage patients, leaving millions of Alzheimer’s sufferers without disease‑modifying benefit.
- Lecanemab & Donanemab show modest slowing of cognitive decline (≈20% in early‑stage patients) but cannot reverse damage (Science China Press).
- CRISPR/Cas9 gene editing is being explored to edit risk genes like APOE ε4, offering a potential one‑time, upstream intervention.
- Senolytic therapies targeting aging glial cells are proposed to rejuvenate brain tissue and complement amyloid‑tau strategies.
- Gut‑brain axis research suggests microbiome modulation could influence neuroinflammation, adding another layer to a multi‑pronged treatment plan.
Alzheimer’s researchers argue that single‑target drugs have stalled because the disease is a tangled web of amyloid‑β, tau, genetics, aging and systemic health. New approaches—combining antibodies, gene‑editing, senolytics and gut‑brain interventions—aim to treat the condition as a complex system rather than a single pathology.
